CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENTCo-Development and Commercialization Agreement • December 3rd, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • London
THIS CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is made and entered into as of August 26, 2010 (the “Effective Date”), by and between IntelGenx Corp., a Canadian corporation (“IntelGenx”), and RedHill Biopharma Ltd., an Israeli company (“RedHill”). IntelGenx and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • December 3rd, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • New South Wales
This Asset Purchase Agreement is made and entered into as of August 11, 2010 (the "Effective Date"), by and among Giaconda Limited ABN 68 108 088 517, an Australian public limited company having its registered office at Ground Floor, 44 East Street, Five Dock, NSW 2046 Australia (the "Seller") and RedHill Biopharma Ltd., an Israeli company, having its business address at 42 Givati Street, Ramat-Gan 52232, Israel (the "Buyer").
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 3rd, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • England
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into effective as of November 18, 2009 (the “Effective Date”), by and between Egalet a/s, a Danish corporation also registered under the name BM Research a/s (“Egalet”), and RedHill Biopharma Ltd., an Israeli company (“RedHill”). Egalet and RedHill each may be referred to herein individually as a “Party,” or collectively as the “Parties”.
RESEARCH and TECH TRANSFER, MANUFACTURING AND SUPPLY AGREEMENT FOR RHB-104 [Clinical Trial Batches Only]Tech Transfer, Manufacturing and Supply Agreement • December 3rd, 2012 • RedHill Biopharma Ltd. • Pharmaceutical preparations • Quebec
This TECH TRANSFER, MANUFACTURING AND SUPPLY AGREEMENT (“Agreement”) is made as of this 28th day of April, 2011, (the «Effective Date») by and between 7810962 CANADA INC., a corporation having its principal place of business at 245 Victoria Ave, Suite 100, Montreal, QC H3Z 2M6, Canada, (“PROVIDER”) and RedHill Biopharma Ltd., with principle place of business at 42 Givati St. Ramat-Gan 52232, Israel (“CUSTOMER”). UMAN and CUSTOMER shall be collectively referred as the “Parties”, with each being a “Party”.
